TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05105529

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Exercise
Description: Cycling at 60% of VO2max on a cycle ergometer for 30 minutes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Cycling at 60% of VO2max on a cycle ergometer for 30 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ozone
Description: Breathing 170ppb ozone

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Filtere Air
Description: Breathing filtered air
Study: NCT05471024

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Digitized Mounted Articulator Scan
Description: Conventional articulator facebow mounting will be digitized using extraoral digital 3d scanner and used to position the maxillary cast on the virtual articulator. This positioning will be utilized during design of the occlusal surface of the restoration.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Average Positioning on Virtual Bonwill Triangle
Description: Virtual Bonwill triangle will be used to position the maxillary cast on the virtual articulator.~This positioning will be utilized during design of the occlusal surface of the restoration.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital Face Scan
Description: Digital face scan will be used to position the maxillary cast on the virtual articulator.~This positioning will be utilized during design of the occlusal surface of the restoration.
Study: NCT04732780

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05116683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-101
Description: Patients will be given ATX-101 at 60 mg/m2 IV weekly in continuous 21 day cycles.
Study: NCT05772689

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Caregivers assigned to the usual care group will be enrolled in the course at the 3-month mark after consenting. All caregivers will then participate in quantitative interviews at post- 6months of their baseline
Study: NCT04933253

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saline irrigation
Description: Mediastinal irrigation with 2 L of 37 degree Celsius saline prior to chest closure
Study: NCT05772689

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caring While Black
Description: Caregivers assigned to this group will receive a schedule for their completion of the course over the next 2 months and supplemental course materials through the mail. The Canvas platform will enable the course to monitor everyone's movement in the cohort through the asynchronous part of the course. Nudges and reminders will be sent twice a week via text or email with the participant's consent.
Study: NCT05852938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BION-1301
Description: BION-1301 Pre-Filled Syringe (PFS) 600mg subcutaneous administration every 2 weeks for 104 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - PFS subcutaneous administration every 2 weeks for 104 weeks.
Study: NCT06471088

Intervention type: DRUG
Intervention: Dovprela
Description: Daily dose: 200 mg
Study: NCT04739995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose naltrexone
Description: 4.5 mg LDN/day for 1 year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low-dose naltrexone
Description: 4.5 mg LDN/day for 1 year
Study: NCT05299502

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional Intervention
Description: 4 individual 1-hour in person (or virtual, according to potential public health restrictions and patients' preference) motivational interviews (12, 18, 24 and 30 weeks) with a registered dietitian will be conducted to elaborate S.M.A.R.T. (Specific,Measurable, Attainable, Relevant, Timely) goals regarding diet, based on the 2019 Canada's Food Guide. Between those individual follow-ups, 4 phone calls with the registered dietitian will be provided (15, 21, 27, 33 weeks). Throughout the study, 10 informative nutritional video clips will also be provided. Participants receiving the intervention will have access to an online Facebook private community to discuss and share experiences, thus maintaining motivation and providing social support.
Study: NCT05789914

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flap surgery+bone graft+guided tissue regeneration
Description: after flap elevation and debridement, intrabony defect was filled with Bio-Oss and covered with membrane.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flap surgery+bone graft+guided tissue regeneration
Description: after flap elevation and debridement, intrabony defect was filled with Bio-Oss and covered with membrane.
Study: NCT04682795

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle-free injector
Description: Using needle-free injector as insulin carrier to treat T2DM

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin pen
Description: Using insulin pen as insulin carrier to treat T2DM
Study: NCT05920512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium valproate extended-release tablets
Description: Sodium valproate extended-release tablets 0.5g/day; sirolimus tablets 1mg/day and calcitriol capsules 0.25μg/day.
Study: NCT05743205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: voluntary consultative wellness session
Description: Professional wellness counseling sessions provided to health care professionals through voluntary enrollment. Consultative sessions will conducted throughout the course of 1 year and number of subsequent sessions will be determined by the participant.
Study: NCT05284487

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jalosome® soothing gel
Description: Jalosome® Soothing gel is a phospholipid based vesicular system based on hyaluronic acid (HA). HA supports the process of formation of extracellular matrix and collagen synthesis by fibroblasts, favoring the formation of a well-vascularized granulation tissue and thus accelerating the healing process. Jalosome® Soothing gel contains other active ingredients: Acetyl-L-carnitine which plays an important role as shuttle for energy production and is involved in cellular metabolism. It is an effective cytoprotective, anti-inflammatory, neuroprotective, metal chelator, anti-apoptotic and anti-oxidant agent. Allantoin is a key constituent of comfrey (Symphytum officinale L), it has moisturizing and keratolytic effect, increasing the water content of the extracellular matrix and enhancing desquamation of upper layers of dead skin cells. Hydrogenated phosphatidylcholine is a permeation enhancers, which increases the solubilization of active ingredients, improving their skin permeation ability.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo does not contain the active ingredients of Jalosome, only the co-formulants.
Study: NCT05795088

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous theta burst stimulation
Description: Two sessions of continuous theta burst stimulation over primary motor cortex to explore synaptic plasticity in Patients with Parkinson's disease
Study: NCT01894308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: 10,30,50 and 70 mg doses of micronized Testosterone delivered by means of a new liquid transdermal delivery solution, HypoSpray(R)once daily for 7 days or until halted due to systemic or dermal reactions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: 10,30,50 and 70 mg doses of micronized Testosterone delivered by means of a new liquid transdermal delivery solution, HypoSpray(R)once daily for 7 days or until halted due to systemic or dermal reactions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pump Sprayer
Description: A dose of product solution is delivered by means of a metered pump spray.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pump Sprayer
Description: A dose of product solution is delivered by means of a metered pump spray.
Study: NCT06074679

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open cholecystectomy
Description: The experimental group and the control group were changed to open cholecystectomy when the operation was difficult to complete.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open cholecystectomy
Description: The experimental group and the control group were changed to open cholecystectomy when the operation was difficult to complete.
Study: NCT05779631

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: mpMRI plus a same-day cystoscopic bladder biopsy
Description: mpMRI plus a same-day cystoscopic bladder biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TURBT
Description: Transurethral resection of the bladder tumor
Study: NCT05971875

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vNOTES vs Vaginal Hysterectomy
Description: Comparison of vNOTES vs VH

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vNOTES vs Laparoscopic Hysterectomy
Description: Comparison of vNOTES vs LH
Study: NCT05677269

Intervention type: PROCEDURE
Intervention: Laparoscopic excision of endometriosis, including colorectal endometriosis
Description: Laparoscopic resection of deep endometriosis, including colorectal endometriosis, in a (candidate) level 2 centre of expertise. Complete resection can exist of either 'shaving' of the nodule from the bowel (leaving the lumen closed), discoid excision or segmental resection, depending on the nodule size and extent of disease.
Study: NCT05711511

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional obturation technique
Description: cold lateral condensation ,this technique involves placing a single cone of gutta-percha (GP) with sealer in the prepared root canal and adding secondary GP cones that are compacted together with the use of a spreader. The cones stay together due to frictional grip and the presence of a sealer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional obturation technique
Description: cold lateral condensation ,this technique involves placing a single cone of gutta-percha (GP) with sealer in the prepared root canal and adding secondary GP cones that are compacted together with the use of a spreader. The cones stay together due to frictional grip and the presence of a sealer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Obtura II
Description: is a popular warm gutta-percha technique that uses a gun to warm and inject the gutta-percha filling into the root canal.Obtura 2 system: The gutta-percha is heated from temperature range of 160C to 200C which is then injected through the needle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Obtura II
Description: is a popular warm gutta-percha technique that uses a gun to warm and inject the gutta-percha filling into the root canal.Obtura 2 system: The gutta-percha is heated from temperature range of 160C to 200C which is then injected through the needle
Study: NCT05987514

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: multimodal ultrasound
Description: contrast-enhanced ultrasound and shear wave elastography on liver target lesion
Study: NCT04701606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artecom® (pyronaridine-artesunate)
Description: \* Participant body weight (Artecom® dose)~* ≥ 65kg (Artecom® 4 tablets: Pyronaridine 720mg/ Artesunate 240mg)~* ≥ 45kg and \< 65kg (Artecom® 3 tablets: Pyronaridine 540mg/ Artesunate 180mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: \* Participant body weight (Placebo dose)~* ≥ 65kg (Placebo 4 tablets)~* ≥ 45kg and \< 65kg (Placebo 3 tablets)
Study: NCT05382806

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Flumazenil
Description: During the procedure, continuous infusion of remimazolam dose of 2mg/kg/hr. when procedure ends, infusion remimazolam stops and 0.9% normal saline or 0.2mg of flumazenil according to allocated groups.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flumazenil
Description: During the procedure, continuous infusion of remimazolam dose of 2mg/kg/hr. when procedure ends, infusion remimazolam stops and 0.9% normal saline or 0.2mg of flumazenil according to allocated groups.
Study: NCT06261840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole 500 mg
Description: Multi-dose oral MTZ (500 mg twice daily for 7 days) for the treatment of T. vaginalis infection in women and men

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secnidazole 2000 MG
Description: Single-dose 2 g oral SEC for the treatment of T. vaginalis infection in women and men
Study: NCT05299151

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular exercises
Description: The vestibular exercise program basically consists of 3 groups of exercises: adaptation, substitution, and habituation exercises. It is aimed to provide vestibular adaptation with adaptation exercises. Exercises that include visual and somatosensory cues to improve gaze and postural stability constitute substitution exercises. Balance exercises can be performed with eyes open and closed, or somatosensory cues can be changed by performing them on soft ground. Removing or reducing clues allows the patient to use other systems as well. The basis of habituation exercises is the reduction of the pathological response as a result of repeated exposure to the provocative stimulus. Habituation is specific to the type, intensity, and direction of stimuli. In most cases, the movement that stimulates the pathological response is less frequently performed during daily activities and promotes compensation for the initially abnormal signal of treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard neurorehabilitation exercises
Description: A neurorehabilitation program based on stretching, strengthening, posture, mobilization, static and dynamic balance exercises (standing on one leg, tandem, balance board, etc.) will be applied.
Study: NCT04638413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking (W)
Description: Participants engage in 30 min of walking daily, for three weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking + PolyRules! (W+PolyRules!)
Description: Participants alternate between 30 min of walking on half of the days and 30 min of gamified inhibitory control on the other days.
Study: NCT05371158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online intervention
Description: The first module includes psychoeducation on neuropathic pain and CIPN (Table 1). Participants acquaintance themselves with intervention goals and mindfulness exercises central to ACT. In subsequent modules, participants learn about the aversive effects of pain avoidance, gain insight into their personal values, and work on pain acceptance. Participants exercise to recognize unhelpful thoughts about their pain and learn the difference between the subjective (judging) and objective self, and think about concrete actions to prevent relapse. The intervention primarily consists of text and experiential exercises, complemented with illustrations, metaphors and audio (mp3) files. Additional functionalities may be an outline of experiences by other CIPN patients and/or the ability to keep a diary. Participants in the experimental condition will receive therapist guidance.
Study: NCT05677269

Intervention type: PROCEDURE
Intervention: In vitro fertilisation or intracytoplasmic sperm injection
Description: IVF/ICSI treatment trajectory (maximum of 3 cycles), according to the local protocol. Preferably preceded by 3 months downregulation with either Gonadotrophin-releasing hormone (GnRH) analogue or oral contraceptive pill. One IVF/ICSI cycle is defined as the transfer of all the embryos created after one follicle puncture until pregnancy confirmation or failure of the last embryo transfer.
Study: NCT04421365

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: neurofeedback brain-computer interface (BCI)
Description: The integrated components of BCI system include the high-density EEG, 3D-VR, and a built-in ML platform as a real-time neural signal decoder and neurofeedback controller.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: neurofeedback brain-computer interface (BCI)
Description: The integrated components of BCI system include the high-density EEG, 3D-VR, and a built-in ML platform as a real-time neural signal decoder and neurofeedback controller.
Study: NCT06245486

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Crispact®
Description: Contains 20 Bld CFU/Stick of probiotic Lactobacillus crispatus M247

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Crispact®
Description: Contains 20 Bld CFU/Stick of probiotic Lactobacillus crispatus M247

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06387927

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home exercise program
Description: Patients in group B were taught the core stability exercise in the first visit they received Arabic printed booklet for exercise description repetitions with diagrams in addition to Arabic illustration videos, they received a weekly telephone call to ensure their compliance to the exercise \& motivation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: the core stability exercise
Description: supervised conventional core stability exercise
Study: NCT06505616

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compared the trombogenicity of the Solacea dialyzer with synthetic dialyzers after progressively decreasing heparin until discontinuing it
Description: The duration of the study was four weeks, carried out in two phases. After screening, patients were randomized to be dialyzed with the Solacea™ hemodialyzer versus the usual hemodialyzer, which in all cases had to be a synthetic membrane. In both arms, heparin was progressively decreased until it was discontinued. Afterwards the patients were crossed over to the other arm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compared the trombogenicity of the Solacea dialyzer with synthetic dialyzers after progressively decreasing heparin until discontinuing it
Description: The duration of the study was four weeks, carried out in two phases. After screening, patients were randomized to be dialyzed with the Solacea™ hemodialyzer versus the usual hemodialyzer, which in all cases had to be a synthetic membrane. In both arms, heparin was progressively decreased until it was discontinued. Afterwards the patients were crossed over to the other arm.
Study: NCT06299930

Intervention type: PROCEDURE
Intervention: Neoadjuvant chemotherapy
Description: Patients received neoadjuvant chemotherapy (either taxane-or anthracycline-based, or any cytotoxic chemotherapy) , followed by surgery and radiotherapy

Intervention type: PROCEDURE
Intervention: Adjuvant chemotherapy
Description: Patients received adjuvant chemotherapy (either taxane-or anthracycline-based, or any cytotoxic chemotherapy) after surgery, followed by radiotherapy
Study: NCT05479916

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low glycated milk protein
Description: 40 grams of protein dissolved in 600 mL of water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High glycated milk protein
Description: 40 grams of protein dissolved in 600 mL of water
Study: NCT05404945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 400 mg IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab 400 mg IV
Study: NCT05109429

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neutral Cue-induced Craving
Description: For the neutral cue condition, the participant will be seated in front of a 16-inch monitor and instructed to sit upright to view 20 pictures of water bottles via E-Prime software (Psychology Software Tools Inc., PA), presented for five seconds each in randomized order. The images will include pictures of a water bottle alone, water being poured from a bottle to a glass, and an individual drinking from a bottle of water. Next, participants will watch as research staff open a bottle of water, pour it into a glass, and place it on a table in front of the participant. Participants will also be asked to look at a water bottle, hold it, sniff it, and take a drink of water.
Study: NCT06229990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Injection
Description: After taking furosemide at 1.5 mg/kg intravenously, if the urine output exceeds 200 mL within 2 hours, the patients are going to withhold CRRT. But if there is no response, the titration of furosemide to 2.5 mg/kg and 3.5 mg/kg every 6 hours is scheduled according to the urine output \>200 mL in 2 hours (not exceeding 250 mg).
Study: NCT06279962

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey questionnaire
Description: The intervention is being assigned to one of the 8 different versions of the survey vignette.
Study: NCT05109429

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Opioid Cue-induced Craving
Description: For the visual opioid cue-induced craving condition, the participant will again be seated in front of a 16-inch monitor and instructed to sit upright to view 20 pictures of opioid-related imagery, presented for five seconds each in a randomized order. The opioid-related imagery will be customized for heroin or prescription opioids based upon the participant's primary opioid of choice. The images will include pills and white powder, stages of drug taking preparation (e.g., holding spoon over flame, pills being crushed).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual and Tactile Opioid Cue-induced Craving
Description: For the visual and tactile opioid cue condition, procedures will differ depending on the participants' most preferred route of administration. . Intranasal users will be instructed to watch as research staff opens a wallet, removes a $1 bill, removes a packet of powder mimicking heroin/crushed pills, open the packet, and roll the dollar bill. The participant will then be given the packet and the dollar bill to hold for approximately 30 seconds. Intravenous users will be instructed to watch the research nurse open the packet of fake heroin, pour its contents into a spoon, added a few drops of water to the spoon, hold an open flame from a lighter under the spoon, add cotton to the spoon, and draw the fluid into a syringe.